Biotech is a wild ride. Honestly, if you’ve ever looked at a chart of the Nasdaq Biotechnology Index, you know it looks less like a steady climb and more like an EKG of someone having a minor heart attack. It’s volatile. It’s expensive. But for decades, the Fidelity Select Biotechnology Portfolio Fund (FBIOX) has been the go-to vehicle for investors who want a piece of the "cure for cancer" pie without having to bet their entire retirement on a single clinical trial.
You’ve probably seen the ticker FBIOX pop up on your 401(k) menu. It’s one of the oldest names in the game, launched way back in 1985. Think about that for a second. This fund was around when the first recombinant DNA drugs were just hitting the market. It’s seen the Human Genome Project, the CRISPR revolution, and the COVID-19 vaccine sprint. It’s not just a fund; it’s a living history of biological science as a business.
What is the Fidelity Select Biotechnology Portfolio Fund anyway?
Basically, FBIOX is an actively managed mutual fund. That’s a big deal in a world dominated by passive ETFs like IBB or XBI. While an ETF just follows an index, this Fidelity fund has actual human beings—currently led by Rajiv Kaul—making calls on which companies are likely to actually get a drug through the FDA gauntlet.
They don't just buy everything. They look for the "moats."
In the biotech world, a moat isn't a castle defense; it’s a patent. It’s a proprietary manufacturing process for biologics that is so hard to replicate that competitors just give up. The fund typically holds anywhere from 150 to 200 stocks, but it’s pretty top-heavy. The big names you know—Amgen, Vertex Pharmaceuticals, Regeneron—usually soak up a lot of the capital. Why? Because they have revenue. In biotech, revenue is a luxury. Most small-cap firms are just burning through cash like a bonfire, hoping a Phase III trial doesn't blow up in their faces.
The Rajiv Kaul Era
Rajiv Kaul has been at the helm since 2005. That kind of longevity is rare in the mutual fund world. When you buy into the Fidelity Select Biotechnology Portfolio Fund, you’re essentially buying into Kaul’s brain. He’s known for a "growth-at-a-reasonable-price" (GARP) approach, though "reasonable" is a relative term when you’re dealing with companies trading at 40 times earnings.
He tends to favor companies with platforms, not just products. If a company has a "platform," it means their tech can produce dozens of different drugs. If they just have a "product," and that one drug fails a trial? Game over. The fund tries to avoid those binary "all or nothing" traps that kill retail investors.
✨ Don't miss: Why "Ask Me About It" Is Actually the Best Networking Hack You Aren't Using
The Performance Reality Check
Let's be real. Biotech hasn't been the darling of Wall Street lately. Rising interest rates are a nightmare for this sector.
Why? Because biotech companies need to borrow tons of money to fund research that might not pay off for ten years. When money is expensive, these companies get crushed. Between 2021 and 2023, the sector felt like a ghost town. But the Fidelity Select Biotechnology Portfolio Fund managed to navigate it better than most small-cap heavy ETFs because it leans into the "Big Biotech" titans that have actual cash on their balance sheets.
Over the long term—we’re talking 10 to 20 years—the fund has historically outperformed the S&P 500. But the swings are stomach-churning. You can see 30% gains in a year followed by 20% drops. It’s not for the faint of heart. If you can’t handle seeing your investment lose a quarter of its value in six months, you probably shouldn't be in a sector fund.
Fees, Expenses, and the "Fidelity Tax"
Every actively managed fund has a cost. For FBIOX, the expense ratio usually hovers around 0.69% to 0.75%.
Compare that to a cheap Vanguard S&P 500 index fund that costs 0.03%. It feels high. You’re paying for the research team, the access to company management, and the expertise to tell the difference between a revolutionary gene therapy and a scientific pipe dream. Is it worth it?
- Active Management: In biotech, "buying the index" means you’re buying a lot of junk along with the gems.
- The Alpha Factor: If Kaul picks the next big weight-loss drug winner (like the GLP-1 craze), the extra 0.70% fee becomes irrelevant.
- Turnover: This fund moves. It’s not a "buy and hold for 50 years" situation. The managers trade frequently to lock in gains or cut losses.
The M&A Catalyst
One reason people still flock to the Fidelity Select Biotechnology Portfolio Fund is the hope of an acquisition.
Big Pharma companies—the Pfizer and Merck’s of the world—have a "patent cliff" problem. Their old blockbuster drugs are losing patent protection. They have billions in cash and need new drugs. What do they do? They go shopping. They buy the small biotech firms that the Fidelity team has spent years scouting. When a company in the portfolio gets bought out at a 50% or 100% premium overnight, it sends the fund's NAV (Net Asset Value) through the roof.
What Most People Get Wrong About Biotech Funds
People think biotech is just "healthcare." It’s not.
Healthcare is steady. Healthcare is your local hospital and UnitedHealth Group. Biotech is tech. It’s high-stakes R&D. If you buy this fund thinking it’s a "defensive" play for a recession, you’re going to have a bad time. Biotech often trades more like Bitcoin or AI stocks than it does like a boring healthcare provider.
🔗 Read more: Why Women of Color International Networks are Quietly Changing Global Trade
Also, don't confuse this with the Fidelity Advisor Biotechnology Fund. They are similar, but the "Select" version is usually what retail investors access directly through Fidelity. The Advisor version often comes with "loads" (commissions) if you buy it through a broker. Avoid the load if you can.
Weight-Loss Drugs and the New Frontier
You can't talk about biotech in 2026 without talking about metabolic health. The explosion of GLP-1 agonists—drugs like Ozempic and Mounjaro—changed the landscape. While these are currently dominated by Eli Lilly and Novo Nordisk (which aren't always the primary focus of a "pure" biotech fund like FBIOX), the ripple effects are everywhere.
The Fidelity Select Biotechnology Portfolio Fund has been pivoting toward the "next gen" of these treatments. We're talking oral versions, drugs that preserve muscle mass while losing fat, and gene therapies that might fix metabolism permanently. This is where the active management shines. A human can see the trend; an index just follows the market cap.
Actionable Insights for Investors
If you’re thinking about adding the Fidelity Select Biotechnology Portfolio Fund to your portfolio, don't just dive in headfirst. The water is choppy.
1. Check Your Concentration
Look at your current holdings. If you already own a Total Stock Market fund or a Healthcare ETF, you already own the big biotech names. Adding FBIOX increases your "tilt" toward this sector. Make sure you actually want that. Most experts suggest keeping sector-specific bets like this to 5% or 10% of your total portfolio.
📖 Related: Jordan Belfort and Stratton Oakmont: What Really Happened Behind the Hype
2. Use New Money or Rebalance
Biotech is notoriously cyclical. The best time to buy into FBIOX is usually when everyone else is complaining about how "biotech is dead." When the sector is on the front page of every news site because of a new "miracle cure," it’s probably too late.
3. Watch the Interest Rate Environment
Keep an eye on the Fed. Biotech thrives when rates are low or falling. If we’re in a "higher for longer" interest rate world, expect FBIOX to struggle compared to the broader market.
4. Minimums and Accessibility
Fidelity has made it easier lately, often doing away with the $2,500 minimum for many investors, especially within IRAs. If you’re a small investor, you can usually start with as little as $1.
5. Tax Sensitivity
Because this fund has high turnover (it sells stocks often), it can generate capital gains distributions. If you hold this in a regular taxable brokerage account, you might get a tax bill even if the fund's price didn't go up. It is almost always better to hold the Fidelity Select Biotechnology Portfolio Fund inside a tax-advantaged account like a 401(k), 403(b), or IRA.
The bottom line? This fund is a heavyweight. It’s survived market crashes, regulatory shifts, and the transition from chemistry-based drugs to biological ones. It isn't a "get rich quick" scheme, but as a long-term play on the human desire to live forever (or at least live healthier), it’s hard to ignore. Just make sure you have the stomach for the ride.